Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 13/20 | 0.53 |
| ▸ | FLT4 | P35916 | 13/20 | 0.53 |
| ▸ | KDR | P35968 | 13/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514080 | 0.90 | FLT1 (0.62) | FLT1FLT4KDRMAPTTP53 | |
| SCHEMBL5966466 | 0.87 | FLT1 (0.55) | FLT1FLT4KDRSMN1; SMN2MEN1 | |
| Tasisulam SCHEMBL29376914 | 0.87 | FLT1 (0.62) | FLT1FLT4KDR | |
| Tasisulam SCHEMBL1581371 | 0.87 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL5966613 | 0.87 | FLT1 (0.55) | FLT1FLT4KDRSMN1; SMN2MEN1 | |
| SCHEMBL5966555 | 0.87 | SMN1; SMN2 (0.49) | FLT1FLT4KDRSMN1; SMN2MEN1 | |
| Tasisulam SCHEMBL1662355 | 0.86 | FLT1 (0.61) | FLT1FLT4KDR | |
| SCHEMBL5966441 | 0.82 | FLT1 (0.62) | FLT1FLT4KDRMEN1KMT2A | |
| SCHEMBL5966459 | 0.82 | FLT1 (0.60) | FLT1FLT4KDRSMN1; SMN2MEN1 | |
| SCHEMBL31487879 | 0.82 | FLT1 (0.49) | FLT1FLT4KDRMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20100291592-A1 | NOVEL MARKER FOR SENSITIVITY AGAINST SULFONAMIDE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| CN-1298709-C | Thiophene-amd thiazolesulfonamides as antineoplastic agents | LILLY CO ELI (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1442030-B1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | LILLY CO ELI (US) | 2006-08-30 | — | — | EP | disclosed |
| CN-1575286-A | Thiophene-amd thiazolesulfonamides as antineoplastic agents | LILLY CO ELI (US) | 2005-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | FLT1 76/4885FLT4 51/4885KDR 31/4885 |
| US-20090047365-A1 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent | TOP1, TOP2A, TOP2B | FLT1 220/4885FLT4 181/4885KDR 231/4885 |
| US-20080286282-A1 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor | KDR, FLT4, FLT1 | FLT1 3/4885FLT4 2/4885KDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.